Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study*

Author： Philipp Thomas   Glazer Robert D.   Zhao Yanxing   Pospiech Rainer  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.1, 2009-01, pp. : 187-193

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy

By Sinkiewicz W.   Glazer R. D.   Kavoliuniene A.   Miglinas M.   Prak H.   Wernsing M.   Yen J.  

Current Medical Research and Opinion, Vol. 25, Iss. 2, 2009-02 ,pp. : 315-324

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy

By Schunkert H   Glazer R.D.   Wernsing M.   Yen J.   Macarie C.E.   Vintila M.M.   Romanova J  

Current Medical Research and Opinion, Vol. 25, Iss. 11, 2009-11 ,pp. : 2655-2662

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy

By Ke YuanNan   Zhu DingLiang   Hong HuaShan   Zhu JunRen   Wang RuoNan   Cardenas Pamela   Zhang Ying  

Current Medical Research and Opinion, Vol. 26, Iss. 7, 2010-07 ,pp. : 1705-1713

Informa Healthcare

Access to resources Recommend Favorite

An open‐label extension long‐term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 72, Iss. 2, 2018-02 ,pp. : 84-94

John Wiley & Sons Inc

Access to resources Recommend Favorite

A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis

By Finn William F.   Joy Melanie S.    

Current Medical Research and Opinion, Vol. 21, Iss. 5, 2005-05 ,pp. : 657-664

Informa Healthcare

Access to resources Recommend Favorite